French scientist Etienne-Emile Baulieu, inventor of the abortion pill, dies at 98
ROME (AP) — French scientist Etienne-Emile Baulieu, best known as the inventor of the abortion pill, died on Friday aged 98 at his home in Paris, his institute said in a statement.
Both a doctor and a researcher, Baulieu was known around the world for the scientific, medical and social significance of his work on steroid hormones.
'His research was guided by his attachment to the progress made possible by science, his commitment to women's freedom, and his desire to enable everyone to live better, longer lives,' the Institut Baulieu said in the statement posted on its website.
Born Etienne Blum in Strasbourg on Dec. 12, 1926, he took the name 'Émile Baulieu' when he joined the French Resistance against the Nazi occupation at the age of 15.
An endocrinologist with a doctorate in medicine completed in 1955 and one in science eight years later, in 1963 Baulieu founded a pioneering research unit working on hormones at INSERM, the French institute for health and medical research. He remained as head of the unit until 1997.
He is best known for his development, in 1982, of RU 486, the so-called 'abortion pill' that changed the lives of millions of women throughout the world, offering them the possibility of voluntary medical termination of pregnancy, in physical and psychological safety.
The Institut Baulieu said it was 'a non-invasive method, less aggressive and less delayed than surgery,' noting that following his discovery the researcher faced fierce criticism and even threats from opponents of women's abortion rights.
'Even today, access to this method is opposed, banned in some countries, and is currently being challenged in the United States, where it is the most widely used abortion method,' the institute added.
Baulieu's research into DHEA, a hormone whose secretion and anti-aging activity he had discovered, led him to work on neurosteroids -- or steroids of the nervous system. He also developed an original treatment to combat depression, for which a clinical trial is currently underway in several university hospitals.
In 2008, he founded the Institut Baulieu to understand, prevent and treat neurodegenerative diseases such as Alzheimer's.
Honored with the grand crosses of the Légion d'honneur (legion of honor) and the Ordre national du Mérite (national order of merit), he was elected to the French Academy of Sciences in 1982, which he chaired in 2003 and 2004.
He was a member of the national advisory committee on life sciences and health (1996-2002) and received numerous awards, both in France and abroad.
French President Emmanuel Macron paid tribute to Baulieu in a post on X, calling him 'a beacon of courage' and 'a progressive mind who enabled women to win their freedom.'
'Few French people have changed the world to such an extent,' he added.
After the death of his first wife, Yolande Compagnon, he remarried, to Simone Harari Baulieu. He is survived by three children, eight grandchildren and nine great-grandchildren, his institute said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
24 minutes ago
- New York Times
Inside Paris chaos: Violence and disorder prove familiar footnote to historic game
Desire Doue's deflected shot had barely had time to nestle in the net before the first firework broke across the sky in the eastern Paris suburb of Montreuil. Here, as across the French capital, fans piled into bars and cafes, squeezed themselves onto beer-garden benches and crowded around televisions in their sitting rooms to witness Paris Saint-Germain's historic 5-0 annihilation of Inter in the Champions League final. Advertisement It was a success that had been a long time coming: five years since PSG's only previous appearance in the final, 14 years since the club's agenda-changing takeover by Qatar Sports Investments, 32 years since hated rivals Marseille had claimed France's first — and hitherto only — men's Champions League success. PSG may be a young football club, having only come into being in 1970, but their supporters, young and old, had been waiting for this moment their entire lives. Expectation had turned into tension in the days preceding the game and the nearer it came, the greater the tension grew. But then, in the blink of an eye, the tension was gone. Doue's goal made it 2-0 after only 20 minutes and when he added PSG's third goal with half an hour remaining, shortly to be followed by a fourth, and then a fifth, the cork came off the bottle, turning the entire city into a riot of booming fireworks, bright flares, honking car horns and deliriously celebrating fans. Very quickly, however, and well before the game in Munich had finished, a darker note crept into the celebrations as disturbing videos began to pop up on social media. Cars burning in the streets. Bus stops smashed. Groups of youths flooding across the Peripherique ring road, bringing traffic to a standstill. A young man violently robbed of his scooter. A cyclist left slumped in the road after being knocked from his Velib rental bicycle by a car. Shockingly graphic images showing the aftermath of a collision between a car and a group of people, this time in the south-eastern city of Grenoble, which left two people seriously injured. On the Avenue des Champs-Elysees, police deployed water cannon and tear gas to disperse supporters who attempted to break through crash barriers in order to reach the Arc de Triomphe at the top of the iconic cobbled street. Running battles between troublemakers and members of the CRS, France's notorious riot police, continued throughout the night. Advertisement 'We arrived on the Champs and we saw the first lines of CRS,' says Mathieu Faurie, who was out watching the celebrations and witnessed some of the disorder first-hand. 'We got to the first shops and some people started smashing the windows in Foot Locker. Behind us, the police started tear-gassing people, so there was a moment of panic and everyone started running towards the top of the street. 'It started to get chaotic everywhere. There were crowds of people surging this way and that. People were trying to leave but the cops weren't letting people down the side streets — you had to walk back down the street towards the Place de la Concorde. 'It took a long time to get out and that killed the atmosphere a bit but we carried on towards Grands Boulevards, where there were loads of people, and it was much better.' At Place de la Bastille, east of the city centre, fans massed in their thousands to celebrate PSG's triumph. But a journalist from the German newspaper BILD reported having had to take shelter at the back of a restaurant after it came under attack from rioters. 'Paris made it 4-0. Again, there was great cheering. But this turned into hatred,' wrote Torsten Rumpf. 'The guests in the restaurant were attacked with fireworks and bottles, chairs and tables were thrown. Windows were broken. Fights broke out. 'I saw children and young women crying and heard loud screams. The air became stuffy with the smoke from the fireworks. After 10 minutes, the security guards brought the situation under control.' The French authorities reported that 491 arrests were made in Paris during the night of the game. Paris prefect of police Laurent Nunez told a press conference that 192 members of the public and nine police officers had been injured. In Paris, a 23-year-old scooter rider was killed after being hit by a car, while in the southwest town of Dax, a 17-year-old boy died after being stabbed in the chest. Investigations into both incidents are under way. Advertisement France's Interior Minister Bruno Retailleau posted on social media that 'barbarians have taken to the streets of Paris'. If it was a tragic footnote to append to a significant football match, it was also familiar. The following afternoon, a helicopter hovers in the overcast sky above the River Seine as PSG supporters exit the Invalides metro station and make their way across the Pont Alexandre III towards the Champs-Elysees for their team's triumphant trophy parade. Ousmane Toure, clad in a PSG home shirt and accompanied by his girlfriend, Angeline, had watched the match along with 45,000 fellow fans on the big screens at the Parc des Princes the night before. 'The atmosphere was incredible,' he says with a smile. 'Truly memorable.' But after setting out across Paris on his scooter after the game to revel in the festivities, he saw scenes that left him with memories that he will not look back on with any kind of fondness at all. 'I went out on the Periph (ring road) and it was a bit of a s*** show, to be honest,' he says. 'There were lots of people — I don't know where they'd come from — on motorbikes, blocking the traffic. They were trying to have a party but it wasn't very cool for the people in the cars. 'You'd go past certain streets and there were scenes of chaos. It was unfortunate because it gives a bad image of football and a bad image of the people of Paris. They should have been scenes of joy and they turned into scenes of horror.' On either side of the bridge, street vendors have opportunistically set up stalls offering refrigerated drinks. Cars speed past honking their horns, some twirling PSG flags and scarves from their windows, while youngsters in small groups nimbly dart and weave their way through the crowds on bicycles. Although the atmosphere is relaxed and festive, the sound of police sirens and the whir of the helicopter's blades serve as reminders that the authorities remain on high alert. Advertisement Eliot Nivet, strolling across the bridge with his friend, Pierre-Francois Kerbrat, says that the scenes that had marred the previous evening's celebrations were simply par for the course. 'It started kicking off during the match, which shows it can't have been connected to real supporters,' he says. 'We went to the Champs after and I was there from 11 o'clock until two in the morning. There were fires, like there always are; bikes that were set on fire but nothing out of the ordinary. 'Then the police did their job. There was a fair amount of tear gas. There were just loads and loads of people in every street. There was so much fervour and it's difficult to contain. We're not worried about today.' Arriving on the Right Bank of the Seine on Sunday, police have blocked off Avenue Winston Churchill, which leads straight to the Champs-Elysees. Three dark-grey police vans are parked across the street. Beside one of them, a black-clad police officer eyes the small crowd that has formed beside the crash barriers and mutters something into his walkie-talkie. The supporters there seem more concerned about missing the parade than inadvertently wandering into a riot. There were further skirmishes between supporters and riot police shortly before the trophy procession, as reported by L'Equipe. The clashes continued during Sunday evening, with Reuters reporting that police deployed tear gas when dozens of ticketless fans sought to enter the security perimeter, and again after supporters threw fireworks at police as the stadium emptied out. It was something of an achievement that it was even allowed to take place at all. Mindful of the scenes of serious disorder that had marred a previous PSG trophy parade in 2013 at the Place du Trocadero, which overlooks the Eiffel Tower, Paris authorities were initially minded to reject the club's request before being persuaded into performing a U-turn. Advertisement To cite a more recent example, Liverpool supporters will not need reminding of the carnage that took place before and after the 2022 Champions League final at the Stade de France, where fans were kettled and tear-gassed by police prior to the game, and then picked off by opportunistic muggers as they left the stadium afterwards. Patrick Mignon, a sports sociologist and author, says that eruptions of violence around sporting events in Paris reflect the underlying mistrust that exists between the police and disaffected young people from the city's disadvantaged suburbs. 'When you get events like this, which bring masses of people into the streets, they're an opportunity for people to display the tensions that exist within French society and the phenomenon of political polarisation,' he says. 'The conflict between young people from working-class neighbourhoods and the police is an old story. We also had riots here in 2022 and 2005. Paris is the place where all the tensions within French society are focused. 'We also know that any event that brings lots of people into the streets for a party also attracts young people who see these events as opportunities for all kinds of criminal activity: looting shops, pickpocketing, seeking confrontations with other young people or provoking the police.' Even at the most glorious moments in France's footballing history, tragedy has seldom been far away. After the great Saint-Etienne squad of the mid-1970s returned from beating Dutch side PSV in the European Cup semi-finals in 1976, one of the fans who rushed onto the runway at Boutheon airport to greet them was killed by the plane's propellers. When crowds flocked to the Champs-Elysees to celebrate France's victory over Brazil in the 1998 World Cup final, a panicked driver drove her car into a crowd at the Arc de Triomphe, killing one person and injuring 35. Two men died in different areas of France during the celebrations that followed Les Bleus' triumph at the 2018 World Cup, which also prompted scenes of violent disorder on the Champs-Elysees. Advertisement Of course, excessive celebration, enormous crowds of people and alcohol have proven to be a deadly combination after all manner of sporting events across the world. But as they sweep away the broken glass and patch up the wounded in Paris, there is no shrugging off a troubling sense of deja vu. (Header photo:)
Yahoo
2 hours ago
- Yahoo
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence Therapeutics' initial physical presence in the United States, reinforcing its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters. The new laboratory, located at Cambridge Scientific Labs in Watertown, will allow Defence Therapeutics to further develop and optimize its proprietary Accum® technology for antibody-drug conjugates ("ADCs"). Establishing a presence in the Boston-Cambridge area provides the company with access to top-tier scientific resources and opportunities for collaboration within the region's renowned biotech ecosystem. The Cambridge Scientific Labs location will serve as a short-term base while Defence Therapeutics evaluates options for a long-term facility in the area. "Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market." About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information: Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. The acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal will add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.
